MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.

Iñaki EgurenEva Fernández de PiérolaGracián CampsPaula Martín-MuñozMaría CamposDoina CuculescuInmaculada Aguilera-BuenosvinosInmaculada Rodríguez LópezRafael Salido-VallejoRaluca AlexandruCarlos E De AndreaLaura Álvarez-GigliPedro Berraondo Ignacio Melero BermejoMiguel F Sanmamed

Published in: Journal for immunotherapy of cancer (2024)

Humanized MHC-dKO immunodeficient mice allow and refine the preclinical testing of immunotherapy agents for which experimentation is precluded in conventional immunodeficient mice due to severe xGVHD.

Keyphrases

high fat diet induced
wild type
early onset
type diabetes
metabolic syndrome
mesenchymal stem cells
bone marrow
drug induced